Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molnupiravir versus placebo in non-hospitalized adults with COVID-19
jRCT2031210148Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Molnupiravir with Placebo (2 arms). Primary endpoints: Percentage of participants who are hospitalized and/or die, Percentage of participants with an adverse event and 1 more. Started Aug 2021; status: completed.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210148.